Vaccine · Immune activation · developed by Liquidia Technologies
LIQ001 is a vaccine given as a single vaccination at doses of 0.45 mg or 1.8 mg. It is studied in influenza.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01224262 | Phase 1/2 | Influenza | Completed | LQDA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Influenza
Updated Oct 18, 2026. Something wrong or missing? Report it on the LQDA page.
See LQDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LQDA catalysts and pipeline →